Technology Press Releases

Published on May 3, 2021 - 12:00 GMT

Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa ...

Data provide further evidence for the central role of IRAK4 in inflammation in hidradenitis suppurativa and support both the degrader rationale for targeting IRAK4 and KT-474 development KT-474 is in Phase 1 clinical development as a first-in-class oral …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on May 3, 2021 - 12:00 GMT

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be …

Distribution channels:

Published on May 3, 2021 - 11:30 GMT

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on May 3, 2021 - 11:30 GMT

Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the ...

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α- …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on May 3, 2021 - 11:30 GMT

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End …

Distribution channels:

Published on May 3, 2021 - 11:30 GMT

Bel Reports First Quarter 2021 Results

JERSEY CITY, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a designer, manufacturer and provider of products that power, protect and connect electronic circuits, today announced preliminary financial results for the first …

Distribution channels: Media, Advertising & PR, Technology ...

Published on May 3, 2021 - 11:30 GMT

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical …

Distribution channels: Media, Advertising & PR, Technology ...

Published on May 3, 2021 - 11:30 GMT

Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2

COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant …

Distribution channels: Media, Advertising & PR, Technology ...

Published on May 3, 2021 - 11:05 GMT

Akoustis Locks Process Flow for Second Wafer Level Package for XBAW Filters

New Packaging Solution Addresses the Small Form Factor Requirements for 5G Mobile and WiFi 6E Devices Packages Will Be Manufactured Both In-House and in Outside Supply Chain to Provide Rapid Prototyping and Flexible Capacity Micro Package Compatible Across …

Distribution channels: Media, Advertising & PR, Technology ...

Published on May 3, 2021 - 11:05 GMT

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with ...

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on May 3, 2021 - 11:05 GMT

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property ( …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...